MCCP
MCRB icon

Mission Creek Capital Partners’s Seres Therapeutics MCRB Stock Holding History

Mission Creek Capital Partners’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,000
Closed -$490K – 234
2020
Q4 		$490K Buy
+1,000
New +$586K 0.15% 147

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mission Creek Capital Partners's MCRB Position: Q1 2021 in Review

Mission Creek Capital Partners sold out of Seres Therapeutics (MCRB) in Q1 2021, closing a stake of 1,000 shares — an estimated $490K sold.

Mission Creek Capital Partners first reported a position in MCRB in Q4 2020 and held it in 1 quarter. The position peaked at $490K in Q4 2020. 152 funds tracked by Wall St. Rank hold MCRB as of Q1 2021.

  • Mission Creek Capital Partners reported no remaining Seres Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Mission Creek Capital Partners sold 1,000 Seres Therapeutics shares in Q1 2021, an estimated $490K.
  • Mission Creek Capital Partners first reported a position in Seres Therapeutics in Q4 2020 and held it in 1 quarter.
  • Mission Creek Capital Partners's Seres Therapeutics position peaked at $490K in Q4 2020.
  • 152 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2021.

Based on Mission Creek Capital Partners's 13F filing for Q1 2021, filed 14 May 2021.